Cargando…

Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle’s maneuver for hepatocellular carcinoma: a randomized controlled trial

BACKGROUND: A previous randomized controlled trial demonstrated that intermittent Pringle’s maneuver (IPM) with a 25-min ischemic interval could be applied safely and efficiently in hepatectomy for patients with hepatocellular carcinoma (HCC). But prolonging the hepatic inflow clamping time will ine...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yang, Xu, Liangliang, Wang, Ning, Wei, Yonggang, Wang, Wentao, Xu, Mingqing, Jiang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651268/
https://www.ncbi.nlm.nih.gov/pubmed/37526089
http://dx.doi.org/10.1097/JS9.0000000000000622
_version_ 1785147616378486784
author Huang, Yang
Xu, Liangliang
Wang, Ning
Wei, Yonggang
Wang, Wentao
Xu, Mingqing
Jiang, Li
author_facet Huang, Yang
Xu, Liangliang
Wang, Ning
Wei, Yonggang
Wang, Wentao
Xu, Mingqing
Jiang, Li
author_sort Huang, Yang
collection PubMed
description BACKGROUND: A previous randomized controlled trial demonstrated that intermittent Pringle’s maneuver (IPM) with a 25-min ischemic interval could be applied safely and efficiently in hepatectomy for patients with hepatocellular carcinoma (HCC). But prolonging the hepatic inflow clamping time will inevitably aggravate the ischemia-reperfusion injury. Therefore, we aimed to evaluate the effect of prophylactic dexamethasone on alleviating surgical stress for HCC patients with a 25-min ischemic interval. METHODS: From December 2022 to April 2023, patients who met the inclusion criteria were randomly assigned to the dexamethasone group or control group. Perioperative data and short-term survival outcomes between the two groups were recorded and compared, and subgroup analysis was performed. RESULTS: Two hundred and seventy patients were allocated to the dexamethasone group (n=135) and control group (n=135). Patients in the dexamethasone group had lower area under the curve of serial alanine aminotransferase (AUC(ALT)) (P=0.043) and aspartate aminotransferase (AUC(AST)) (P=0.009), total bilirubin (TB) (P=0.018), procalcitonin (PCT) (P=0.012), interleukin-6 (IL-6) (P=0.006), incidence of major complication (P=0.031) and shorter postoperative hospital stay (P=0.046) than those in the control group. Subgroup analysis showed that the dexamethasone group experienced milder hepatocellular injury than the control group for patients with cirrhosis, and for patients without cirrhosis, the dexamethasone group experienced milder inflammatory response. Moreover, the dexamethasone group preserved better liver function and experienced milder inflammatory response for patients undergoing major hepatectomy, although the hepatocellular injury was not significantly improved. CONCLUSION: Preoperative dexamethasone administration can help improve perioperative outcomes for HCC patients when applying IPM with a 25-min ischemic interval in hepatectomy.
format Online
Article
Text
id pubmed-10651268
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-106512682023-11-15 Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle’s maneuver for hepatocellular carcinoma: a randomized controlled trial Huang, Yang Xu, Liangliang Wang, Ning Wei, Yonggang Wang, Wentao Xu, Mingqing Jiang, Li Int J Surg Original Research BACKGROUND: A previous randomized controlled trial demonstrated that intermittent Pringle’s maneuver (IPM) with a 25-min ischemic interval could be applied safely and efficiently in hepatectomy for patients with hepatocellular carcinoma (HCC). But prolonging the hepatic inflow clamping time will inevitably aggravate the ischemia-reperfusion injury. Therefore, we aimed to evaluate the effect of prophylactic dexamethasone on alleviating surgical stress for HCC patients with a 25-min ischemic interval. METHODS: From December 2022 to April 2023, patients who met the inclusion criteria were randomly assigned to the dexamethasone group or control group. Perioperative data and short-term survival outcomes between the two groups were recorded and compared, and subgroup analysis was performed. RESULTS: Two hundred and seventy patients were allocated to the dexamethasone group (n=135) and control group (n=135). Patients in the dexamethasone group had lower area under the curve of serial alanine aminotransferase (AUC(ALT)) (P=0.043) and aspartate aminotransferase (AUC(AST)) (P=0.009), total bilirubin (TB) (P=0.018), procalcitonin (PCT) (P=0.012), interleukin-6 (IL-6) (P=0.006), incidence of major complication (P=0.031) and shorter postoperative hospital stay (P=0.046) than those in the control group. Subgroup analysis showed that the dexamethasone group experienced milder hepatocellular injury than the control group for patients with cirrhosis, and for patients without cirrhosis, the dexamethasone group experienced milder inflammatory response. Moreover, the dexamethasone group preserved better liver function and experienced milder inflammatory response for patients undergoing major hepatectomy, although the hepatocellular injury was not significantly improved. CONCLUSION: Preoperative dexamethasone administration can help improve perioperative outcomes for HCC patients when applying IPM with a 25-min ischemic interval in hepatectomy. Lippincott Williams & Wilkins 2023-07-31 /pmc/articles/PMC10651268/ /pubmed/37526089 http://dx.doi.org/10.1097/JS9.0000000000000622 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-sa/4.0/This is an open access article distributed under the Creative Commons Attribution-ShareAlike License 4.0 (https://creativecommons.org/licenses/by-sa/4.0/) , which allows others to remix, tweak, and build upon the work, even for commercial purposes, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-sa/4.0/ (https://creativecommons.org/licenses/by-sa/4.0/)
spellingShingle Original Research
Huang, Yang
Xu, Liangliang
Wang, Ning
Wei, Yonggang
Wang, Wentao
Xu, Mingqing
Jiang, Li
Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle’s maneuver for hepatocellular carcinoma: a randomized controlled trial
title Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle’s maneuver for hepatocellular carcinoma: a randomized controlled trial
title_full Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle’s maneuver for hepatocellular carcinoma: a randomized controlled trial
title_fullStr Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle’s maneuver for hepatocellular carcinoma: a randomized controlled trial
title_full_unstemmed Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle’s maneuver for hepatocellular carcinoma: a randomized controlled trial
title_short Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle’s maneuver for hepatocellular carcinoma: a randomized controlled trial
title_sort preoperative dexamethasone administration in hepatectomy of 25-min intermittent pringle’s maneuver for hepatocellular carcinoma: a randomized controlled trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651268/
https://www.ncbi.nlm.nih.gov/pubmed/37526089
http://dx.doi.org/10.1097/JS9.0000000000000622
work_keys_str_mv AT huangyang preoperativedexamethasoneadministrationinhepatectomyof25minintermittentpringlesmaneuverforhepatocellularcarcinomaarandomizedcontrolledtrial
AT xuliangliang preoperativedexamethasoneadministrationinhepatectomyof25minintermittentpringlesmaneuverforhepatocellularcarcinomaarandomizedcontrolledtrial
AT wangning preoperativedexamethasoneadministrationinhepatectomyof25minintermittentpringlesmaneuverforhepatocellularcarcinomaarandomizedcontrolledtrial
AT weiyonggang preoperativedexamethasoneadministrationinhepatectomyof25minintermittentpringlesmaneuverforhepatocellularcarcinomaarandomizedcontrolledtrial
AT wangwentao preoperativedexamethasoneadministrationinhepatectomyof25minintermittentpringlesmaneuverforhepatocellularcarcinomaarandomizedcontrolledtrial
AT xumingqing preoperativedexamethasoneadministrationinhepatectomyof25minintermittentpringlesmaneuverforhepatocellularcarcinomaarandomizedcontrolledtrial
AT jiangli preoperativedexamethasoneadministrationinhepatectomyof25minintermittentpringlesmaneuverforhepatocellularcarcinomaarandomizedcontrolledtrial